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Previewsiron metabolism (e.g., the PCBPs), and
perhaps the metabolism of other transi-
tion metals, may be guided by simple
molecular signatures that are yet to be
discovered.
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Tumors display distinct metabolic programs, and altered lipid metabolism is emerging as an important pro-
cess in cancer. In this issue, Yue et al. (2014) report that aberrant cholesteryl ester accumulation is found in
advanced prostate cancers with PTEN loss and PI3K/AKT activation. Importantly, inhibition of cholesterol
esterification impaired cancer aggressiveness.Cancer cells frequently display alterations
in their metabolic activity compared to
their nontumorigenic counterparts. The
most prominent of these is the Warburg
effect, whereby cancer cells consume
higher amounts of glucose even in the
presence of molecular oxygen (aerobic
glycolysis). Additionally, cancer cells un-
dergo changes in their metabolic activity
to facilitate biomass accumulation and
anabolic growth. These include alter-
ations in lipid metabolism orchestrated
by the sterol regulatory element-binding
protein (SREBP) transcription factors,
which regulate genes involved with fatty
acid (FA) and cholesterol biosynthesis
(Currie et al., 2013). Increased activity of
SREBP and overexpression of its down-
stream targets has been reported in
several cancers, and ablation of SREBP
has been shown to impair growth of glio-
blastoma cells (Griffiths et al., 2013; Guoet al., 2009). Furthermore, particular com-
ponents of the de novo lipogenic machin-
ery, such as fatty acid synthase (FASN),
are upregulated in several cancers, asso-
ciated with the overexpression of known
oncogenes, and have been the focus
of substantial drug development efforts,
highlighting the desirability and tracta-
bility of targeting lipid metabolism in
cancer. Yue et al. (2014) add to
this by providing a novel quantitative
approach to classifying prostate cancers
based on cholesteryl ester (CE) accu-
mulation and that CE storage poten-
tiates PI3K-dependent SREBP activity,
thereby fueling cancer aggressiveness.
Crucially, this process can be exploited
therapeutically.
The detection of lipid metabolism in
cancer cells, particularly in intact tissues,
represents a technical challenge. Lipids
exist in different subcellular compart-ments, such as lipid droplets (LDs),
cellular organelles consisting of triacylgly-
cerides, sterols and phospholipids that
are crucial for the storage and hydrolysis
of neutral lipids. Utilizing label-free
Raman spectromicroscopy to quantita-
tively investigate LD composition at the
single cell level, Yue et al. (2014) revealed
an accumulation of CEs in high-grade and
metastatic prostate cancers but not in
normal prostate, benign prostatic hyper-
plasia (BPH), prostatitis, or prostatic intra-
epithelial neoplasia (PIN) specimens.
Accurate patient stratification, by identi-
fying those who require further interven-
tion and establishing which therapies will
be most efficacious, is an important step
in successfully treating cancer. The au-
thors demonstrate that CE accumulation
could be utilized to accurately identify
patients who require further treatment,
as it is a better predictivemarker of cancer
Figure 1. SREBP-Dependent Regulation of Lipid Uptake and Cholesterol Metabolism Promotes Prostate Cancer Cell Survival and
Proliferation
(A–D) Normal cells do not display hyperactivation of the PI3K/Akt/SREBP signaling cascade. SREBP activity is further constrained by free cholesterol accumu-
lation (A). Aggressive prostate cancer cells frequently display increased PI3K/Akt/SREBP activity due to loss of PTEN. SREBP activity is potentiated by ester-
ification and compartmentalization of cholesterol into lipid droplets, allowing the uptake of essential fatty acids. This promotes proliferation, migration, and
invasion of cancer cells— and potentially influences their interaction with the tumor microenvironment (B). ACAT-1 inhibition perturbs cholesterol esterification
and results in cholesterol accumulation, inhibition of SREBP activity, reduced lipid uptake, and inhibition of growth (C). Supplementation of exogenous lipids, in
the form of LDL or AA, reinstates proliferation in cells where ACAT-1 is inhibited (D).
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Previewsaggressiveness compared to current his-
tological classification methods.
In addition, this study revealed novel
aspects of the intricate regulation of lipid
metabolism in cancer. Cholesterol esteri-
fication requires the activity of acetyl-
CoA acetyltransferase (ACAT-1). In
noncancer cells accumulation of choles-
terol inhibits SREBP activity through
the sterol-dependent negative feedback
loop resulting in reduced lipogenesis. In
contrast, high-grade prostate cancer cells
utilize ACAT-1 to esterify and store
excess cholesterol to prevent cellular
toxicity and allow continuous SREBP ac-
tivity. This maintains high expression of
the low-density lipoprotein receptor
(LDLR) and uptake of essential lipids,
including arachadonic acid, thereby pro-
moting unrestrained proliferation and
growth (Figure 1) (Yue et al., 2014).
SREBPactivity is drivenby hyperactiva-
tion of the PI3K/AKT/mTORC1 signaling
cascade, one of the most frequently acti-
vated pathways in cancer. Loss of PTEN,
a negative regulator of this pathway, alsorepresents an important step in the pro-
gression to hormone-refractory prostate
cancer. Interestingly, CE accumulation
correlated with androgen-independence
and PTEN loss. Moreover, the presence
of CE-rich LDs seems to support the
migratory and invasive capacity of pros-
tate cancer cells, as ACAT-1 knockdown
or pharmacological inhibition suppressed
this ability in vitro (Figure 1). Furthermore,
ACAT-1 inhibition perturbed cell viability
and reduced tumor xenograph growth
in vivo, without adverse effect on other
tissues or bodyweight.
In addition to identifying ACAT-1 as a
potential therapeutic target, this study
also demonstrates that cancer cells have
evolved different mechanisms that lead
to the sustained activation of SREBP.
This facilitates enhanced de novo lipid
biosynthesis in cancer cells but also the
increased uptake of essential FAs. It also
highlights the importance of different lipid
classes for the transformed phenotype of
cancer cells. Unsaturated FAs, particu-
larly arachidonic acid, are importantCell Metabolismprecursors for signaling lipids such as
prostaglandins, which regulate cell migra-
tion and tumor-stroma interactions
(Baenke et al., 2013). Thus, disrupting
FA synthesis and desaturation or uptake
of essential FAs is likely to have profound
effects on signaling events at the cancer
cell level and also impact on the tumor
microenvironment.
It is now clear that the PI3K/Akt/
mTORC1 pathway targets SREBP in mul-
tiple ways, including induction of SREBP
processing, regulation of protein stability
and modulation of its subnuclear localiza-
tion (Shao and Espenshade, 2012). The
modulation of cholesterol levels by
ACAT-1 now further increases the spec-
trum of interactions between this impor-
tant signaling axis and lipid metabolism.
These findings also suggest that the
presence of CE-rich LDs could be
used to stratify patients who should
receive more aggressive therapy and
that cholesterol esterification could
itself be a therapeutic target. One out-
standing question is whether cholesterol19, March 4, 2014 ª2014 Elsevier Inc. 351
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Previewsesterification and LD formation could also
be relevant in other tumor types. For
instance, clear cell renal cell carcinomas
(ccRRCs) are characterized by the pres-
ence of glycogen stores and abundant
LDs (Straub et al., 2010). Indeed, ccRCCs
display vastly elevated levels of free
cholesterol and cholesteryl esters
compared to normal kidney tissue (Geb-
hard et al., 1987). Targeting cholesterol
esterification could thus also have benefits
in other cancer types. Interestingly, ACAT
inhibitors have already undergone toxico-
logical analysis and are used in humans.
Avasimibe, the agent used to inhibit
ACAT in this study, is currently
undergoing clinical trials for the treatment
of hyperlipidemia and atherosclerosis.
Like statins or metformin, this may provide
another example of a drug originally devel-
oped to targetmetabolic diseases that can
be repurposed for the treatment, and
possibly prevention, of cancer. Old drugs
could indeed perform new tricks when
used in the appropriate setting (Gronich
and Rennert, 2013).
However, there are also cautionary
notes raised by the work presented in
this paper. Interestingly, supplementation352 Cell Metabolism 19, March 4, 2014 ª201of culture medium with exogenous low-
density lipoprotein (LDL) or arachidonic
acid rescued the toxicity of ACAT inhibi-
tors (Figure 1). Although the authors did
not investigate the effect of exogenous
lipids in vivo, this result suggests that die-
tary regimens that produce elevated
levels of circulating LDL or AA could
restrict ACAT inhibitor efficacy (Yue
et al., 2014). This observation comple-
ments previous results demonstrating
that the lipolytic enzyme monoacylgly-
cerol lipase (MAGL) is important in
aggressive cancers and that its ablation
resulted in reduced tumor growth. How-
ever, this effect was completely lost
when mice were fed a high-fat diet (No-
mura et al., 2010). The impact of diet on
the metabolism of cancer cells is an
urgent issue. Dietary regimens should be
considered during preclinical research
and then be translated into the clinic if
potential targets in cancer metabolism
are to fulfill their promise.REFERENCES
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The thermogenic capacity of brown adipose tissue (BAT) in response to cold is relatively well established in
humans. Several hormones and factors are involved in this response, and Lee et al. (2014) now provide
evidence for a role of irisin and FGF21 in BAT thermogenic activity in humans.In response to low-temperature exposure
or prolonged stay in a mild cold environ-
ment, warm-blooded animals may initiate
shivering, a muscular response aimed at
maintaining the proper body temperature.
However, before the surrounding temper-
ature decreases enough to activate shiv-
ering, a nonshivering phase occurs, in
which brown adipose tissue (BAT) is acti-vated for heat production. This response
involves rapid (within minutes) activation
of signal transduction via neuronal path-
ways and heat release via UCP-1 induc-
tion in BAT sites such as the supraclavic-
ular region (Symonds et al., 2012). Among
the known factors and hormones involved
in this response is norepinephrine (NE),
which mediates the activation of thesympathetic nervous system. NE induces
fibroblast growth factor 21 (FGF21)
gene transcription and release in BAT
(Hondares et al., 2011), which, in turn
promotes lipolysis by the activation of
hormone sensitive lipase (HSL). Conse-
quently, the intracellular lipids released
by lipolysis within brown adipocytes are
directed to active mitochondria for heat
